These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10944975)

  • 21. Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey.
    Wang KF; Chang CC; Wang KL; Wu CH; Chen LC; Lu TM; Lin SJ; Chiang CE
    J Chin Med Assoc; 2014 Feb; 77(2):61-7. PubMed ID: 24332414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management.
    Zárate A; Manuel-Apolinar L; Saucedo R; Hernández-Valencia M; Basurto L
    Arch Med Res; 2016 Oct; 47(7):491-495. PubMed ID: 28262189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of consensus for control of cholesterolemia in Spain].
    Masana L; Pedro-Botet J; Ros E; Rubiés-Prat J
    Med Clin (Barc); 1998 May; 110(15):598-9. PubMed ID: 9650208
    [No Abstract]   [Full Text] [Related]  

  • 25. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between serum cholinesterase and incident hyper-LDL cholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia as well as changes in lipid levels in a health screening population.
    Oda E
    Atherosclerosis; 2015 Jul; 241(1):1-5. PubMed ID: 25935113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Statins, life style and treatment of hypercholesterolemia: the time is changing, criteria too].
    Pintó X
    Med Clin (Barc); 2006 Feb; 126(6):217-9. PubMed ID: 16510095
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypercholesterolemia, cardiovascular risk, and hypocholesteremic treatment in the elderly].
    Cicconetti P; Ciotti V; Tafaro L; Riolo N; Marigliano V
    Recenti Prog Med; 2002 Apr; 93(4):264-72. PubMed ID: 11989134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients].
    Pedro-Botet J; Pintó X
    Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
    Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
    Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Statins under fire: justified or not?].
    Declerck E; De Loof H; De Meyer GR
    J Pharm Belg; 2009 Dec; (4):119-30. PubMed ID: 20183988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document.
    Volpe M; Volpe R; Gallo G; Presta V; Tocci G; Folco E; Peracino A; Tremoli E; Trimarco B;
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):313-329. PubMed ID: 28523635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dyslipidemia and cardiovascular risk in the adult population of Castile-Leon (Spain)].
    Escribano Hernández A; Vega Alonso AT; Lozano Alonso JE; Alamo Sanz R; Castrodeza Sanz JJ; Lleras Muñoz S;
    Gac Sanit; 2010; 24(4):282-7. PubMed ID: 20638754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Eat less fat to prevent ischemic cardiopathy. The potential impact of population and individual strategies for controlling cholesterolemia in Spain].
    Banegas Banegas JR; Rodríguez Artalejo F; Martín Moreno JM; del Rey Calero J
    Med Clin (Barc); 1993 Jun; 101(3):81-6. PubMed ID: 8315989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lipid distribution in the adult population of Catalonia].
    Plans P; Ruigómez J; Pardell H; Salleras L
    Rev Clin Esp; 1993 Jun; 193(1):35-42. PubMed ID: 8337460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hypercholesterolemia and cardiovascular risk: advantages and limitations of current treatment options].
    Cimminiello C; Zambon A; Polo Friz H
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):6S-13. PubMed ID: 27312018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.